Detalhe da pesquisa
1.
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Proc Natl Acad Sci U S A
; 105(10): 3879-84, 2008 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18332425
2.
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
PLoS Pathog
; 3(4): e46, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17411338
3.
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
HIV Clin Trials
; 9(1): 1-10, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18215977
4.
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
HIV Clin Trials
; 8(4): 193-204, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17720659
5.
Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
HIV Clin Trials
; 7(6): 291-308, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17197377
6.
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
J Clin Pharmacol
; 46(3): 265-74, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490802
7.
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
AIDS
; 18(5): 775-9, 2004 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-15075512
8.
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Antivir Ther
; 7(3): 165-74, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12487383
9.
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
J Infect Dis
; 198(2): 234-40, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18540803
10.
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
J Acquir Immune Defic Syndr
; 44(4): 401-10, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17224848
11.
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
J Acquir Immune Defic Syndr
; 43(2): 153-60, 2006 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951643
12.
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
J Infect Dis
; 191(12): 2046-52, 2005 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897990
13.
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
J Infect Dis
; 190(2): 280-4, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15216462
14.
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
J Infect Dis
; 185(5): 599-607, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11865416